The platelet integrin glycoprotein (GP) IIb/IIIa, which mediates platelet aggregation, has been the target for novel antiplatelet agents, the GPIIb/IIIa antagonists. Several GPIIb/IIIa antagonists have been developed based on the peptide RGDS present in adhesion proteins, including the principle ligand fibrinogen. The apoptosis enzyme, procaspase-3, contains an RGD-recognition sequence and is activated by RGDS. We examined the effects of RGDS and several GPIIb/IIIa antagonists on cell death and procaspase-3 activation in rat neonatal cardiomyocytes. These antagonists do not recognize rat integrins, yet RGDS, orbofiban, and xemilofiban induced dose-dependent apoptosis and procaspase-3 activation in cardiomyocytes over 72 h, particularly under hypoxic conditions. Scrambled peptide, the monoclonal antibody 7E3 or integrelin (a peptide containing a KGD sequence), had little or no effect. Immunoprecipitation of procaspase-3 followed by treatment with the compounds showed that procaspase-3 was activated directly by RGDS, orbofiban, xemilofiban, and by monoclonal 7E3 antibody, the latter demonstrating that compounds must enter cells to induce apoptosis through caspase activation. Integrelin had no effect. Binding studies with 3 H-SC52012B, a GPIIb/IIIa antagonist analogue of orbofiban, showed no specific binding to cardiomyocytes, but the radioligand accumulated intracellularly over 72 h.
Integrins are cell surface molecules that are involved in cell adhesion to matrix proteins and other cells. Integrins are also capable of generating intracellular signals on engaging their ligands, including signals involved in cell growth and survival (1, 2) . Glycoprotein (GP) 1 IIb/IIIa is largely confined to platelets and megakaryocytes, although it is also found on some melanoma cells (3) . GPIIb/IIIa is required for normal platelet aggregation, an early event in the development of arterial thrombosis (4) . Several adhesion proteins bind to GPIIb/IIIa, but the principle ligand is fibrinogen (5) . The interaction between fibrinogen and GPIIb/IIIa involves several regions of the ligand, including the motif RGD, two copies of which are found on each ␣-chain of fibrinogen (6) . Several compounds have been designed, based on the RGD sequence, as antagonists of fibrinogen binding (7, 8) . GPIIb/IIIa antagonists prevent platelet aggregation and have been found to prevent coronary artery thrombosis, at least when given as short term infusions.
Several members of the procaspase family of apoptosis genes, including procaspases-1, -2, -3, -7, and -8 also contain RGD motifs (9) . Two of these, procaspase-1 and -3, also contain potential RGD-binding motifs near to the experimentally determined processing sites necessary for activation to the mature caspase. Indeed, RGD-containing peptides are capable of inducing apoptosis in T-cells through direct procaspase-3 activation without any requirement for integrin enagement or modification of integrin-mediated cell signaling (9) . Potentially, RGD-containing peptides act by inducing conformational changes in the procaspase leading to increased oligomerization, a putative step in the activation of the enzyme (10) . Similar activation of procaspase-3 in cardiomyocytes may explain the reported increase in cardiac death in patients on the oral GPIIb/IIIa antagonist, orbofiban. Moreover, such a mechanism may explain the proapoptotic properties of RGD peptides in models of angiogenesis, inflammation, and cancer metastasis (11) (12) (13) .
Activation of caspase-3 is a common ultimate signal in response to factors that induce apoptosis, such as Fas-induced apoptosis in several cell types (14) . Caspase-3 also plays an important role in the apoptosis of cardiomyocytes rendered ischemic (15) . Caspase-3 activates a number of targets, including nuclear enzymes involved in DNA degradation (16) . We investigated if RGD peptides and RGD mimetics induced apoptosis through direct procaspase-3 activation in rat cardiomyocytes. The compounds studied were xemilofiban and orbofiban, designed to mimic the RGD motif (17) . We also examined the effects of the monoclonal anti-GPIIb/IIIa antibody, abciximab, a chimeric mouse/human F(ab) of 7E3, which binds to the ligand binding site of GPIIb/IIIa (18) . We examined the effects of the peptide RGDS and a cyclic peptide, integrelin, which contains a KGD rather than an RGD sequence that is thought to improve its specificity for GPIIb/IIIa (8) . Cell Culture-Primary cultures of neonatal rat cardiomyocytes were prepared by a modification of the method originally described by Simpson and Savion (31) . Briefly, the hearts from 1-3-day-old Wistar rats were minced and dissociated with approximately 80 units/ml type II collagenase and 0.06% pancreatin. Cardiomyocytes were separated from other cell types by Percoll density gradient centrifugation. Dispersed cells were incubated in 25-cm 2 flasks for 30 min at 37°C in a CO 2 incubator. Nonattached, viable cells were collected and seeded into fresh flasks at a density of 1.5 ϫ 10 5 cells/ml. To obtain a near pure cardiomyocyte preparation, cells were incubated in Dulbecco's modified Eagle's medium with Hams F-12 supplemented with 1.2 g/liter sodium hydrogen carbonate, 10% (v/v) newborn calf serum containing 1 mM pyruvic acid, 1 g/ml transferrin, 10 g/ml insulin, 10 ng/ml sodium selenite, 250 M vitamin C, 100 units/ml penicillin G, and 100 g/ml streptomycin. Using a monoclonal anti-␣-actinin sarcomeric antibody we found 96 -98% of our cells were cardiomyocytes (not shown). Medium was replaced with medium containing no newborn calf serum at 48 h. The cells were incubated for 24 h before the addition of the test compounds.
Coating of Streptavidin-coated Dynabeads with Biotinylated Peptides-Amino-terminal biotinylated peptides, b-GRGDSP and b-GRGDNP, were purified by high performance liquid chromatography (by manufacturer) and were Ͼ95% pure. Streptavidin-coated Dynabeads (M-280, 2.8 M diameter, Dynal) were coated with biotinylated peptides according to the manufacturer's instructions. In brief, the Dynabeads were resuspended by vortexing for 2 min, and the required volume was pipetted into a suitable tube, which was placed in the Dynal magnetic protein purification holder and allowed settle for 2 min. The supernatant was removed carefully, and the beads were resuspended in PBS. This procedure was repeated three times. After the third wash, the beads were resuspended in the appropriate volume of PBS for coating of the beads with the biotinylated peptides. The appropriate amount of biotinylated peptides (1 g of peptide to 10 7 beads) was added to washed Dynabeads and incubated for 30 min at 4°C with unidirectional mixing. The beads were collected by placing the sample tube in the Dynal magnetic protein purification holder for 2 min. The supernatant was removed, and the beads were resuspended in PBS. The washing procedure was repeated six times. The beads were then added to cells at the required concentration. 24 -72 h-On day 4 following isolation, medium from cardiomyocytes grown in each 25-cm 2 flask was replaced with fresh medium, 18 flasks in triplicate were used over 24 -72 h each containing vehicle or compound (GRGDSP-scrambled peptide, GRGDSP on beads, RGDS peptide, 7E3, integrelin, orbofiban, or xemilofiban). In additional experiments, we examined the compounds on cardiomyocytes rendered hypoxic. On day 4 following isolation, medium from cardiomyocytes grown in each 25-cm 2 flask was replaced with fresh medium, and the compounds were added as above. The cells were then placed in a hypoxic incubator in an atmosphere of 94% nitrogen, 5% CO 2 , and 1% O 2 for 48 h. Caspase-3 activity was then measured as described below.
Treatment of Normal and Hypoxic Cardiomyocytes with RGDS-containing Peptides and GPIIb/IIIa Antagonists over
Treatment of Human Umbilical Vein Endothelial Cells (HUVEC) with GPIIb/IIIa Antagonists-HUVEC were isolated as has been described previously (20) . On day 2 following isolation, medium from HUVECs grown in 25-cm 2 flask was replaced with fresh medium, and the cells were exposed to orbofiban for 72 h. Caspase-3 activity was measured in these cells as described below.
Measurement of DNA Fragmentation-Apoptosis was measured by quantitating the fragmentation of DNA in the cytoplasm of apoptotic cells. The cell lysate was placed into a streptavidin-coated microtitre plate. Subsequently, a mixture of anti-histone-biotin and anti-DNA-POD antibodies was added and incubated for 2 h. During the incubation period, the anti-histone antibody binds to the histone component of the nucleosomes and simultaneously fixes the immunocomplex to the streptavidin-coated microtitre plate. Additionally, the anti-DNA-peroxidase antibody reacts with the DNA component of the nucleosomes. After removal of unbound antibodies by a washing step, the amount of nucleosomes was quantified by the peroxidase retained in the immunocomplex. Peroxidase activity was determined photometrically with ABTS (z,zЈ-azino-di[3-ethylbenzthiazolin-sulfonat]) as a substrate. A positive control was provided in the assay. Another assay was used to measure apoptosis by quantitating the fragmentation of 5Ј-bromo-2Ј-deoxyuridine-labeled DNA in apoptotic cells. The assay, a sandwich enzyme-linked immunosorbent assay (ELISA), uses two mouse monoclonal antibodies, one directed against DNA and the other against 5Ј-bromo-2Ј-deoxyuridine. Cardiomyocytes were incubated with the nonradioactive thymidine analogue 5Ј-bromo-2Ј-deoxyuridine, which is incorporated into the genomic DNA. 5Ј-bromo-2Ј-deoxyuridine fragments are released from the cells into the cell cytoplasm during apoptosis.
Measurement of Caspase-3 Activity in Cardiomyocytes-
The colorimetric substrate (Ac-DEVD-pNA) was labeled with the chromophore p-nitroaniline (pNA). pNA is released from the substrate upon cleavage by DEVDase (caspase-3). Free pNA produces a yellow color that was monitored by a photometer at 405 nM. The potent, irreversible, and cell-permeable pan-caspase inhibitor Z-VAD-fluoromethylketone was added directly to cells as a control. The difference between the amount of pNA produced in the absence of inhibitor and in the presence of inhibitor is largely a measure of caspase-3 and caspase-7 activity. In order to measure caspase-3 specific activity, cells were also treated with a caspase-3-specific inhibitor, Ac-DMOD-CHO. The difference between the amount of pNA released in the presence and absence of caspase-3 inhibitor minus the pNA released in the presence of the pan caspase inhibitor Z-VAD-FMK was determined as a measure of caspase-3 activity. A pNA calibration curve was plotted from a pNA stock solution provided, and caspase-3 activity in the samples was measured relative to this curve. The caspase-3-specific activity was calculated as follows,
where A A ϭ mean-induced apoptosis sample A 405 Ϫmean blank A 405 , A s ϭ mean negative control caspase-3 specific inhibitor sample A 405 Ϫmean blan kA 405 , and A N ϭ mean negative control pan inhibitor sample A 405 Ϫmean blank A 405 . The activity (X) of caspase-3 present in each sample was calculated using the following formula.
X ϭ pmol of pNA liberated/h in the absence of inhibitor
The protein concentration was determined by the method of Bradford (21) . The specific activity of (SA) caspase-3 in the cell extract was calculated as follows.
SA ϭ pmol liberated/h at 37°C/g of protein (Eq. 3)
Western Blot and Immunoprecipitation Analysis of Procaspase-3 Activation-Following the treatment of cardiomyocytes with RGDS-containing peptides and GPIIb/IIIa antagonists over 72 h, caspase-3 expression and activation was also measured directly by Western blot where the active caspase-3 was detected as its cleaved mature form using a polyclonal rabbit anti-caspase-3 antibody. In brief, for Western blot studies, whole cell lysates were prepared with Triton X-100 buffer containing protease inhibitors. After adjustment for protein concentration, cell lysates were boiled in Laemmli buffer and resolved on 8 -15% gradient SDS-polyacrylamide gel electrophoresis before Western blot analysis with an antibody against caspase-3.
Procaspase-3 was purified by immunoprecipitation from lysates of cardiomyocytes in 10 mM Tris, pH 7.4, 0.15 M NaCl, 1 mM EDTA, 1 mM EGTA, 0.2 mM sodium orthovanadate, 0.5% Nonidet P-40, and 1% Triton X-100 with 20 M caspase-3 selective inhibitor Ac-DMOD-CHO. Extracts were incubated with anti-caspase-3 antibody for 2 h at 4°C, followed by addition the of protein A-Sepharose beads. The immunoprecipitated material was washed three times in lysis buffer. The beads were resuspended in 1 ml of caspase buffer (10 mM HEPES, pH 7.0, 50 mM NaCl, 20% glycerol, 40 mM ␤-glycerophosphate, 2 mM MgCl 2 , 5 mM dithiothreitol) and incubated with 1 mM peptide (GRGDSP or GRADSP) or GPIIb/IIIa antagonists; 10 g/ml monoclonal 7E3 antibody, 10 M integrelin, 10 M orbofiban and 10 M xemilofiban, for 20 min at 30°C. At the end of the incubation an equal volume of Laemmli buffer was added, and the samples were boiled and resolved on 8 -15% gradient SDS-polyacrylamide gel electrophoresis before Western blot analysis with an antibody against procaspase-3 and cleaved fragments.
3 H-SC52021B Rapid Filteration Binding Assay-For the competition binding assay, cardiomyocytes were incubated with:
3 H-SC52012B for 30 min, 3 H-SC52012B with excess SC52012B for 30 min, 3 H-SC52012B for 72 h, 3 H-SC52012B with excess SC52012B for 72 h, or 3 H-SC52012B for 72 h followed by the addition of excess SC52012B over the last 30 min. These cells were washed with PBS three times and either scraped into 1 ml of Hanks/Hepes solution containing 1 mM CaCl 2 (HBSS) or lysed directly in 50 l of 1% Triton X-100 lysis buffer on ice for 30 min. Cells in HBSS and lysis buffer were spun at 10,000 rpm in a bench top centrifuge. The cell pellet of the cardiomyocytes in HBSS was resuspended in 50 l of HBSS. The supernatant of the lysed cardiomyocytes was removed to a clean Eppendorff on ice. The cell pellet suspension in 50 l of HBSS was passed immediately through a cell separator with a Whatman GF/C filter to collect cell membranes. The filters were added to scintillation fluid and analyzed by scintillation counter (Wallac 1214 Rackbeta, Turku, Finland) The lysed supernatant was added directly to 5 ml of scintillation fluid and similarly analyzed. The results were plotted as counts/minute averaged over three flasks.
Measurement of Specific 3 H-SC52021B
Binding to Human Caspase-3-To measure specific binding of 3 H-SC52012B to human recombinant caspase-3, 2 g of caspase-3 or a control milk protein were incubated with the 20 nM 3 H-SC52012B or 20 nM 3 H-SC52012B in the presence of 10 M unlabeled SC52012B or the GPIIb/IIIa antagonists orbofiban, monoclonal antibody 7E3, mAb2, or integrelin for 16 h at 4°C, followed by treatment with activated charcoal to remove free radioligand. The supernatant was then counted directly. The results were plotted as counts/min averaged over three flasks.
Calculation of 3 H-SC52021B Binding Affinity to Human Recombinant Caspase-3-1 g of human recombinant caspase-3 was incubated with increasing concentrations (6.25-1000 nM) of 3 H-SC52021B in the presence and absence of excess 10 M SC-52021B for 16 h at 4°C followed by treatment with activated charcoal to remove free radioligand. The supernatant was then counted directly. The specific activity (ϳ50%) was calculated for each concentration of 3 H-SC52021B (6.25-1000 nM), and the K d and B max values were calculated by standard saturation binding curves and Scathchard plots.
Dual-staining Immunofluorescence and Confocal Microscopy of Cardiomyocytes Treated with Biotinylated
Peptides-Cells were incubated in the presence or absence of biotinylated peptides (GRADSP or GRGDSP) at 1 mM for 48 h. Cells were then washed in warmed PBS, scraped into 1 ml of PBS, and cytospun onto glass slides. Cells were washed and fixed by incubation with ice-cold methanol for 7 min followed by incubation with ice-cold acetone for 2 min. Cells were then washed in PBS for 5 min before being treated with goat serum blocking buffer for 1 h followed by treatment with rabbit-anti-rat-caspase-3 antibody at a dilution of 1/1000 for 1 h. After 1 h, cells were washed in Tris-buffered saline (3 ϫ 5 min) and then treated with secondary goat-anti-rabbit antibody that was conjugated with a flourescent Texas Red dye for 15 min. This step was followed by a washing step in PBS (3 ϫ 5 min) followed by staining of the biotinylated peptides in cells with streptavidin-fluorescein isothiocyanate for 10 min. This dualstaining method allowed us to see specific binding of the biotinylated peptides to caspase-3 inside the cell. Cells were photographed using a confocal microscope (Zeiss LSM510, Axioplan 2). Pictures obtained were magnified at 40 ϫ 10 or 63 ϫ 10.
Statistical Analysis-All quantitative data are expressed as mean Ϯ S.E. The data were analyzed by parametric unpaired Student's t test. p values Ͻ0.05 were considered statistically significant. Figs. 1 and 2 ) measured by either assay of DNA fragmentation, with a corresponding increase in procaspase-3 activation (Figs. 1 and 2) , whereas a scrambled peptide had no effect. No increase in apoptosis was seen when RGDS was first bound to beads. The GPIIb/IIIa antagonists orbofiban and xemilofiban also caused apoptosis and procaspase-3 activation in cardiomyocytes with a similar time course (Fig. 1) . In contrast, the monoclonal antibody 7E3 and the KGD-containing cyclic peptide, integrelin, did not cause apoptosis in the cardiomyocytes, although some procaspase-3 activation was observed at the highest concentration of integrelin after 72 h. In contrast to cardiomyocytes, orbofiban induced only a small degree of procaspase-3 activation in HUVEC and only at a very high concentration (not shown). Caspase-3 activation was also shown in cardiomyocytes by Western blot (Fig. 3A) detection of the cleaved caspase-3 p20 fragment following treatment with RGDS, orbofiban, and xemilofiban over 72 h. RGDS bound to beads; integrelin and the monoclonal antibody 7E3 did not cause activation of caspase-3. Direct caspase-3 activation was shown by immunoprecipitation of procaspase-3 from cardiomyocytes followed by treatment
RESULTS

RGD-containing Peptides and GPIIb/IIIa Antagonists Induce Apoptosis through Procaspase-3 Activation in Cardiomyocytes-RGDS showed a dose-dependent increase in apoptosis of cardiomyocytes over 24 -72 h (
FIG. 1. RGDS and GPIIb/IIIa antagonists cause a dose-dependent increase in apoptosis and procaspase-3 activation in primary rat neonatal cardiomyocytes over 72 h, n ‫؍‬ 3.
A, apoptosis measured as percentage maximum-induced apoptosis by DNA fragmentation ELISA. In control experiments (a, vehicle only; b, 2 mM scrambled peptide; and c, RGDS on beads) apoptosis was not induced. RGDS (d, 300 M; e, 600 M; and f, 2 mM) caused a dose-dependent increase in apoptosis (**, p Ͻ 0.01, ***, p Ͻ 0.001 versus control), whereas 3, 10, and 30 g/ml 7E3 (g, h, I) and 3, 10, and 30 M integrelin (j, k, l) had no effect. Orbofiban (m, n, o) and xemilofiban (p, q, r) each at 3, 10, and 30 M, also caused apoptosis (**, p Ͻ 0.01; ***, p Ͻ 0.001 versus control). B, procaspase-3 activation in cardiomyocytes over 72 h using identical treatments (*, p Ͻ 0.05; **, p Ͻ 0.01; ***, p Ͻ 0.001 versus control).
with the compounds (Fig. 3B) . RGDS, orbofiban, and xemilofiban caused direct activation of caspase-3 measured by Western blot. Interestingly the p20-cleaved fragment was also detected in the monoclonal antibody 7E3-treated protein, suggesting that this compound must enter the cell to cause activation of procaspase-3. Neither RGDS bound to beads nor integrelin caused direct activation of caspase-3.
GPIIb/IIIa Antagonist 3 H-SC52021B Enters the Cell and Binds to a Cytoplasmic Protein-Following incubation of cardiomyocytes with
3 H-SC52021B for 30 min, no significant binding to cardiomyocytes was found (Fig. 4) . After 72 h, however, there was a marked increase in binding confined largely to the cytosolic fraction and not the membrane fraction. The cytosolic labeled ligand was competed off by unlabeled SC-5021B added at the start of the 72-h incubation and not when added for the last 30 min, consistent with a gradual uptake of the labeled compound over the period of incubation.
3 H-SC52021B Binding to Human Recombinant Caspase-3-3 H-SC52021B bound to human recombinant caspase-3 with a K d of 59 Ϯ 2 nM and a B max of 324 Ϯ 32 fmol/g of protein, (n ϭ 3).
3 H-SC52021B binding to human caspase-3 ( Fig. 5 ) was competed by unlabeled SC-52021B, orbofiban, xemilofiban, and by the monoclonal 7E3 antibody. In contrast, integrelin did not compete for binding. Similarly mAb2, a murine GPIIb/IIIa monoclonal antibody that does not bind to the ligand binding site, had no effect on 3 H-SC52021B binding to caspase-3. As a control experiment, we measured the binding of 3 H-SC52021B to milk protein under the same conditions and examined the effects of the compounds.
3 H-SC52021B bound nonspecifically to this protein in that neither unlabeled SC-52021B nor the other GPIIb/IIIa antagonists inhibited binding.
Dual-staining Immunofluorescent Confocal Microscopy Revealed Co-localization of RGDS-biotinylated Peptide to
Procaspase-3-Cells were stained with peptide (green) and an antibody to caspase-3 (red). GRGDSP (Fig. 6C) but not GRADSP (Fig. 6F ) biotinylated peptides bound to procaspase-3 inside the cardiomyocyte (co-localization was stained white).
Orbofiban Shows Enhanced Potency against Hypoxic Cardiomyocytes-Hypoxia (1% O 2 ) caused a significant increase in apoptosis and procaspase-3 activity in cardiomyocytes after 48 h (Fig. 7) . The degree of apoptosis (not shown) and procaspase-3 activation was markedly potentiated by orbofiban even at a concentration as low as 10 nM. The degree of procaspase-3 activation far exceeded that seen in normoxic cells. Neither integrelin nor the monoclonal 7E3 antibody increased the hypoxic-mediated procaspase-3 activation. 1, molecular weight markers) . B, Western blot detection of caspase-3 activity in immunoprecipitated procaspase-3 protein which was treated as above (lanes 1-7) , over 30 min at 30°C.
FIG. 4.
3 H-SC52012B, a GPIIb/IIIa antagonist binds to cytosolic protein in cardiomyocytes after 72 h, n ‫؍‬ 3. Primary rat neonatal cardiomyocytes were incubated with 20 nM 3 H-SC52012B alone or 20 nM SC52012B in the presence of 10 M SC52012B for 30 min or 72 h before harvesting cells. There was no specific membrane or cytoplasmic binding after 30 min. After 72 h there was no membrane binding; however, there was a significant increase (***, p Ͻ 0.001 versus 30-min binding) in cytosolic binding that was suppressed by excess SC52012B ( §, p Ͻ 0.001 versus cytosolic bound ligand).
DISCUSSION
GPIIb/IIIa antagonists are often RGD-mimetics designed to inhibit platelet aggregation by preventing fibrinogen binding to the integrin, ␣ IIb ␤ III . Paradoxically, one of these (orbofiban) has been reported to increase mortality in patients with coronary artery disease. Peptides containing an RGD motif induce apoptosis in resting (G 0 ) peripheral blood T cells (9) . Consequently, we investigated the effects of an RGDS peptide in inducing apoptosis measured by DNA fragmentation in primary rat cardiomyocytes. RGDS peptide caused a dose-dependent increase in apoptosis over 24 -72 h with the half-maximal effect occurring at 300 M after 72 h, whereas the scrambled peptide GRADSP had no effect. Two RGD-mimetics, orbofiban and xemilofiban that have a high degree of specificity for platelet GPIIb/IIIa (17) also caused dose-dependent apoptosis of cardiomyocytes over 24 -72 h. In contrast, the monoclonal antibody 7E3, which is directed against the ligand binding site of GPIIb/IIIa, and the cyclic heptapeptide integrelin, a GPIIb/IIIa antagonist that contains a KGD rather than an RGD sequence, did not induce significant apoptosis. The effect of orbofiban was cell-specific in that it had little effect on HUVEC.
RGD is a common integrin recognition sequence in adhesive proteins, and cardiomyocytes exhibit anchorage-dependent growth. Therefore, a possible explanation for these findings is interruption of integrin-mediated signaling or cell-cell interactions required for cell survival (22) . To address this possibility, we examined the effects of an RGDS-containing peptide (GRGDSP) bound to beads. No apoptosis was seen with the RGDS-coated beads. However, the addition of soluble GRGDSP to this preparation induced apoptosis (not shown).
These results indicated that RGDS peptides must enter cardiomyocytes to induce apoptosis. Indeed, the labeled GPIIb/IIIa antagonist 3 H-SC52012B did not bind to cardiomyocyte cell membranes over 30 min. However, there was a time-dependent increase in 3 H-SC52012B within the cytosolic fraction that peaked at 72 h. In the absence of any specific cell binding, it is unlikely that the uptake of the drug involved a specific protein or transport system. These results suggest that the compounds enter by passive diffusion, as shown previously for RGD-peptides (9) . These compounds are highly charged and may act as zwitterions, so that at the lower pH of the cell, they are retained.
Caspases, derived from their precursor and catalytically inactive procaspases, are a series of degradative enzymes that are final products of programmed cell death (10) . Caspase-3 has been found to mediate the apoptosis that occurs in response to ischemia and doxorubicin in cardiac cells (15) . Caspases contain an RGD motif and in some cases an RGD recognition site that may control protein folding and activation. Caspase-1 contains an RGD motif next to the catalytically active cysteine residue (QAR286GDSP) and a homologous single RGD sequence is found in caspase-2 (QACR304GD) (9) . The large subunit of caspase-3 and caspase-7 and the small subunit of caspase-8 also contain an RGD sequence. RGD-binding motifs found in integrins (D315DA and D180DM) (23) are also found in procaspase-1 and -3, respectively close to experimentally determined processing sites. RGD-containing peptides activate procaspase possibly by inducing conformational changes resulting in the oligomerization and subsequent autoprocessing required for activation. Rat procaspase-3 also contains both an R144GD sequence and a potential RGD-binding site (D180DM) next to the catalytically active cysteine residue (QACR164GT). RGDS, orbofiban, and xemilofiban increased caspase-3 activity in the rat cardiomyocytes after 48 -72 h in parallel with the increase in apoptosis. In contrast, the GPIIb/IIIa antagonist 7E3, a monoclonal antibody, did not cause significant caspase-3 activation potentially as the antibody cannot cross the cell membrane. Integrelin at high concentrations induced a small increase in procaspase-3 activation but to a far lesser extent than seen with either orbofiban or xemilofiban and at a concentration that exceeds by orders of magnitude the concentration required to prevent platelet aggregation (24) . Integrelin is a cyclic peptide containing a KGD rather than an RGD sequence (19) . The lack of effect of integrelin on procaspase-3 may reflect the strict peptide sequence requirement for activation of procaspase-3 (9). When procaspase-3 was immunoprecipitated from cardiomyocytes RGDS, orbofiban, xemilofiban, and 7E3 directly activated procaspase-3, whereas integrelin had no effect. RGD-containing GPIIb/IIIa antagonists activated procaspase-3 directly, whereas non-RGD-containing antagonists like integrelin had no effect. It is possible that the caspases are involved in inducing cell death in cardiomyocytes, including caspase-7, which is also detected in our assay of DEVDase activity.
As procaspase-3 contains an RGD recognition sequence (DDM), we next assessed whether 3 H-SC52012B could bind directly to recombinant human caspase-3 protein using a char- coal adsorption technique for separating bound and free radioligand. 3 H-SC52012B bound to human caspase-3 to a greater extent than to a control milk protein. The addition of unlabeled SC52012B reduced the binding to that seen with the control protein (nonspecific binding to protein or charcoal) indicating that binding to caspase-3 was specific. In contrast, unlabeled SC52012B had no effect on 3 H-SC52012B was displaced by orbofiban and by the monoclonal antibody 7E3. As 7E3 did not induce cell death, this finding further supports the hypothesis that the compounds must gain access to cells in order to activate cell death pathways. In contrast mAb2, an antibody to an epitope on GPIIb/IIIa remote from the ligand binding site (25) , had no effect. Similarly, integrelin at 10 M did not compete with 3 H-SC52012B binding, consistent with the absence of an effect on apoptosis and procaspase-3 activation. There is no evidence of widespread tissue damage in patients receiving GPIIb/IIIa antagonists. Indeed, there was no procaspase-3 activation in HUVEC and no evidence of apoptosis (data not shown). Moreover, the plasma concentrations of orbofiban and xemilofiban inducing apoptosis in cardiomyocytes are far in excess of those achieved at doses used to inhibit platelet aggregation (200 -400 nm) (26) . However, the target population for GPIIb/IIIa antagonists (patients with coronary artery disease) may have or may develop cardiac hypoxia as a result of coronary artery obstruction. Hypoxia has been shown to trigger cell death through activation of procaspase-3 (27, 28) . Consequently, we examined whether stressed cardiomyocytes were more susceptible to the effects of GPIIb/IIIa antagonists. Orbofiban at a concentration as low as 10 nM induced apoptosis and activated procaspase-3 in cardiomyocytes grown in 1% O 2 . Moreover, the degree of apoptosis and enzyme activation exceeded that seen in cardiomyocytes grown under normoxic conditions. Again, neither integrelin nor the monoclonal 7E3 antibody increased procaspase-3 activation in hypoxic cardiomyocytes. It is possible that the hypoxic cells are more susceptible to orbofiban due to FIG. 7 . Orbofiban, but neither integrelin nor the monoclonal antibody 7E3, potentiates procaspase-3 activation in hypoxic cardiomyocytes over 48 h, n ‫؍‬ 3. Hypoxia caused a significant increase in caspase-3 activity in primary neonatal cardiomyocytes (**, p Ͻ 0.01 versus control). Caspase-3 activity was further increased when hypoxic cardiomyocytes were also treated with orbofiban (ϱ, p Ͻ 0.05; ¶, p Ͻ 0.01; and §, p Ͻ 0.001 versus hypoxic cells alone). Neither integrelin nor the monoclonal antibody 7E3 increased caspase-3 activity. increased membrane permeability or due to co-activation of procaspase-3 by hypoxia and the GPIIb/IIIa antagonist.
Numerous studies have shown that the disruption of cellmatrix interactions leads to apoptosis in anchorage-dependent cells (11) , possibly because of a loss of adhesion-mediated survival signals (12, 22) . Consequently, peptides and nonpeptide mimetics based on the RGD motif have been used extensively to inhibit tumor metastasis (11) , abrogate T-cell-mediated immune responses in vivo (13) , induce endothelial cell apoptosis in models of angiogenesis (12) , and inhibit inflammation (29) . Perhaps RGD peptides induce apoptosis through direct caspase-3 activation and therefore may be capable of causing apoptosis in many cell types independent of their interactions with integrins.
The phase III clinical trial of orbofiban, OPUS-TIMI16, was halted recently due to an increase in mortality, largely cardiac in origin. In part, this may have reflected a paradoxical activation of platelets as has been reported for several of these compounds. Interestingly, Shcherbina and Remold-O'Donnell (30) have reported the presence of caspase-3 in human platelets and its activation by platelet agonists. Our results provide an alternate explanation, that under conditions of ischemia or infarction orbofiban contributed to the associated cardiac damage. It is worth noting that the Swissprot data base identifies several proteins, in addition to procaspase-3, that contain both an RGD motif and RGD-binding site and that are important for cardiac function. One of these, the ryanodine receptor controls calcium release from the sarcoplasmic reticulum. Other cardiac proteins with both motifs include transcriptional endoplasmic reticulum ATPase, cytochrome b 5 , the prostaglandin F 2␣ receptor-regulating protein, and myosin. Therefore, the biological activity of RGD peptides and nonpeptide RGD mimetics may be broader than simple interruption of adhesion.
